Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · CHAMPIONS ONCOLOGY, INC. (CSBR)

Champions Oncology revenue rises 8.8% to $15.2 million; net loss narrows to $426,000

Positive Impact 3 of 5 earnings Written later

Champions Oncology reported unaudited first-quarter fiscal 2027 results for the period ended July 31, 2026, with revenue of $15.2 million, up 8.8% from a year earlier. The net loss narrowed to $426,000 from $466,000, and adjusted EBITDA rose to $671,000 from $59,000, though the company still reported a loss and spent more on sales and marketing.

Key points

  • Oncology revenue of $15.2 million, up from $14.0 million in the prior-year quarter
  • Net loss of $426,000 versus $466,000 a year earlier; basic loss per share of $0.03 in both periods
  • Adjusted EBITDA of $671,000 versus $59,000; oncology services margin of 51% versus 43%
  • Sales and marketing expense rose 66.6% to $3.1 million; cash used in operations was $492,000 and cash ended the quarter at $4.4 million with no debt

The filing

CompanyCHAMPIONS ONCOLOGY, INC. (CSBR)
Form8-K, current report
Filed with the SECSep 10, 2026, 4:46 PM ET
Accession number0001628280-26-061383

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 10, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.